

China Journal of Chinese Materia Medica ISSN 1001-5302,CN 11-2272/R

## 《中国中药杂志》网络首发论文

题目: 基于网络药理学的雷公藤效毒作用机制研究

作者: 董一珠,张冰,林志健,张晓朦 DOI: 10.19540/j.cnki.cjcmm.20181119.001

收稿日期: 2018-09-06 网络首发日期: 2018-11-29

引用格式: 董一珠,张冰,林志健,张晓朦.基于网络药理学的雷公藤效毒作用机制研

究[J/OL]. 中国中药杂志. https://doi.org/10.19540/j.cnki.cjcmm.20181119.001





网络首发:在编辑部工作流程中,稿件从录用到出版要经历录用定稿、排版定稿、整期汇编定稿等阶段。录用定稿指内容已经确定,且通过同行评议、主编终审同意刊用的稿件。排版定稿指录用定稿按照期刊特定版式(包括网络呈现版式)排版后的稿件,可暂不确定出版年、卷、期和页码。整期汇编定稿指出版年、卷、期、页码均已确定的印刷或数字出版的整期汇编稿件。录用定稿网络首发稿件内容必须符合《出版管理条例》和《期刊出版管理规定》的有关规定;学术研究成果具有创新性、科学性和先进性,符合编辑部对刊文的录用要求,不存在学术不端行为及其他侵权行为;稿件内容应基本符合国家有关书刊编辑、出版的技术标准,正确使用和统一规范语言文字、符号、数字、外文字母、法定计量单位及地图标注等。为确保录用定稿网络首发的严肃性,录用定稿一经发布,不得修改论文题目、作者、机构名称和学术内容,只可基于编辑规范进行少量文字的修改。

出版确认: 纸质期刊编辑部通过与《中国学术期刊(光盘版)》电子杂志社有限公司签约,在《中国学术期刊(网络版)》出版传播平台上创办与纸质期刊内容一致的网络版,以单篇或整期出版形式,在印刷出版之前刊发论文的录用定稿、排版定稿、整期汇编定稿。因为《中国学术期刊(网络版)》是国家新闻出版广电总局批准的网络连续型出版物(ISSN 2096-4188, CN 11-6037/Z),所以签约期刊的网络版上网络首发论文视为正式出版。

DOI: 10.19540/j.cnki.cjcmm.20181119.001

# 基于网络药理学的雷公藤效毒作用机制研究

董一珠¹,张冰≥1,2,林志健¹,张晓朦¹

(1.北京中医药大学 中药学院,北京 100029;

2.北京中医药大学 中药药物警戒与合理用药研究中心,北京 100029)

⊠通信作者 张冰,博士,教授,博士生导师,主任医师,主要从事中药药物警戒思想研究,Tel:(010)64286335,Email:zhangbing6@263.net

摘要 探讨有毒中药雷公藤中主要成分雷公藤甲素、雷公藤氯内酯醇、雷公藤红素、去甲泽拉木醛、雷公藤春碱、雷公 藤新碱的效毒作用机制。采用 admetSAR 在线评估系统计算雷公藤主要成分的性质,通过多个数据库挖掘并收集成分的 潜在靶点,经生物信息学数据库 DAVID 对潜在靶点进行通路富集。应用 Cytoscape 软件建立"靶点-通路"网络,并对网络 进行拓扑分析。雷公藤主要化学成分均能透过血脑屏障,具有肠渗透性。共预测到靶点 65 个,富集通路涉及癌症信号通 路(pathways in cancer)、乙肝(hepatitis B)、类风湿性关节炎(rheumatoid arthritis)、美洲锥虫病[chagas disease (American trypanosomiasis)]、Toll 样受体信号通路(Toll-like receptor signaling pathway)、细胞凋亡(apoptosis)、结 肠癌(colorectal cancer)、NF-kB 信号通路(NF-kappa B signaling pathway)等。雷公藤主要通过调控炎症信号通路、 癌症信号通路等发挥免疫性疾病及癌症的治疗作用,其毒性作用可能与细胞凋亡以及对药物代谢酶的作用有关。

关键词 雷公藤;ADME/T;网络药理学;药效;毒性

## Pharmacodynamic effect and virulent effect of *Tripterygium wilfordii* based on network pharmacology

DONG Yi-zhu<sup>1</sup>, ZHANG Bing<sup>1</sup>, <sup>2</sup>, LIN Zhi-jian<sup>1</sup>, ZHANG Xiao-meng<sup>1</sup>

(1. School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100029, China

2.Center for Pharmacovigilance and Rational Use of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China) Abstract To investigate the pharmacodynamic effect and virulent effect of the main components of the toxic Chinese medicine Tripterygium wilfordii, such as triptolide, triptolide, tripterine, demethylzeylasteral, wilfotrine and euonine, the admetSAR online assessment system was used to calculate the properties of the main components of T. wilfordii. The potential targets of the components were mined and collected through multiple databases, and the potential targets were enriched by the bioinformatics database DAVID. Cytoscape software was used to establish a "target-pathway" network and perform topology analysis on the network. The main chemical components of T. wilfordii were able to penetrate the blood-brain barrier and had intestinal permeability. A total of 65 targets were predicted, including pathways in cancer, hepatitis B, rheumatoid arthritis, and chagas disease (American trypanosomiasis), Toll-like receptor signaling pathway, apoptosis, colorectal cancer, NF-kappa B signaling pathway, etc. T. wilfordii mainly plays a role in the treatment of immune diseases and cancer by regulating inflammatory signaling pathways and cancer signaling pathways. Its action on apoptosis pathway and drug metabolism enzymes may be the mechanism of its toxicity.

Key words Tripterygium wilfordii; ADME/T; network pharmacology; pharmacodynamics; toxicity

收稿日期:2018-09-06

基金项目:国家自然科学基金项目(81673618);国家重点基础研究发展计划(973)项目(2007CB512605)

作者简介: 董一珠,硕士研究生, E-mail:15736872291@163.com

网络首发时间: 2018-11-29 15:2**网络**首发地址: http://kns.cnki.net/kcms/detail/11.2272.R.20181128.0941.002.html

雷公藤 Tripterygium wilfordii Hook.f.为卫矛科雷公藤属植物,具有祛风除湿、通络止痛等功效,广泛应用于免疫性疾病,如类风湿性关节炎、系统性红斑狼疮等<sup>[1-2]</sup>。雷公藤主要成分包括二萜类、三萜类、生物碱类化合物,在发挥药效的同时也存在不可忽视的毒副作用。雷公藤具有肝、肾、心、消化系统和生殖系统等多器官毒性,其主要成分也是毒性成分<sup>[3]</sup>。网络药理学通过计算机模拟算法,通过运用组学、高通量筛选、分子交换验证及网络分析等技术揭露药物、基因、靶点与疾病之间复杂的网络信号关系<sup>[4]</sup>,阐释中药多成分-多靶点-多途径协同作用机制<sup>[5]</sup>。本研究切入二萜类活性成分雷公藤甲素、雷公藤氯内酯醇;三萜类活性成分雷公藤红素、去甲泽拉木醛;生物碱活性成分雷公藤春碱、雷公藤新碱进行网络药理学研究,对雷公藤药效及毒性作用机制进行探讨。

## 1资料与方法

#### 1.1 化学成分准备

采用 PubChem<sup>[6]</sup>数据库(https://pubchem.ncbi.nlm.nih.gov/)对雷公藤甲素、雷公藤氯内酯醇、雷公藤红素、去甲泽拉木醛、雷公藤春碱、雷公藤新碱进行检索,保存其 smiles 号。

## 1.2 化学成分 ADMET 预测

华东理工大学开发的 admetSAR-1.0<sup>[7]</sup>在线评估系统(http://lmmd.ecust.edu.cn/admetsar1/),预测雷公藤主要成分的 ADME/T 性质,其整体准确率可达 88.9%<sup>[8]</sup>。定性预测指标包括血脑屏障(BBB)、人体小肠吸收性(HIA)、细胞通透性(Caco-2)、CYP 酶底物、CYP 酶抑制剂、AMES 致畸性(AMES toxicity)、致癌性(carcinogens)、鱼毒性(fish toxicity)、四膜虫毒性(*Tetrahymena pyriformis* toxicity)、蜂毒性(honey bee toxicity)、大鼠急性口服毒性(acute oral toxicity)等。定量预测指标包括溶解度(aqueous solubility)、Caco-2 细胞透过性(Caco-2 permeability)、大鼠口服毒性(rat acute toxicity)、鱼毒性(fish toxicity)、四膜虫毒性(*T. pyriformis* toxicity)。

#### 1.3 化学成分靶点预测

采用 TCMSP,SWISS,STICH 在线靶标预测平台,获得化学成分靶点。①利用中药系统药理学分析平台数据库 TCMSP(Version 2.3)<sup>[9]</sup>(http://ibts.hkbu.edu.hk/LSP/tcmsp.php),对其化学成分名称进行检索,整理其对应靶点。②在 SWISS<sup>[10]</sup>在线平台(http://www.swisstargetprediction.ch/)输入化合物 smiles 号,通过结构相似性进行靶标预测,选取预测结果中 probability $\geq$ 0.7 的靶标进行分析<sup>[11]</sup>。③在 STICH(Version 5.0) <sup>[12]</sup>数据库(http://stitch.embl.de/)中输入化合物 smiles 号,收集预测靶点。为了全面收集不同计算方式所得到的雷公藤主要成分的预测靶点,对 3 个数据库所获得的靶点进行去重、汇总处理,并在 Uniprot<sup>[13]</sup>(http://www.uniprot.org/)进行标准化基因名,所有靶点均为人源,最终整合化学成分靶点数据库。

#### 1.4 对成分靶点进行通路富集

利用生物学信息注释数据库 DAVID Bioinformatics Resources  $6.8^{[14]}$ ,(https://david.ncifcrf.gov/)对所预测的化学成分靶点进行通路富集,对 P 进行筛选,保留 P<0.01 的通路,并通过 Omicshare 3.0(http://www.omicshare.com/)进行可视化处理。

#### 1.5 靶点-通络网络构建

利用 Cytoscape 3.3.0 构建靶点-通路网络图,在网络中,靶点和通路以节点(node)表示,靶点和通路之间的联系以边(edge)表示。节点的度数(degree)是与节点相连边的数量,度数越大,说明网络中与该节点直接相关的节点数越多,表明该节点越重要,采用 Cytoscape 中插件 Network Analyzer 对网络拓扑参数度数进行分析<sup>[15]</sup>。

## 2 结果

## 2.1 化学成分 ADMET 预测

## 2.1.1 吸收、分布、排泄相关指标

雷公藤主要成分都能透过血脑屏障并被人体小肠所吸收,均可分布在线粒体中,且均具有较低的生物降解度。其中,雷公藤甲素、雷公藤红素、去甲泽拉木醛有较高的 Caco-2 细胞通透性。具体指标见表 1, 2。

表1 化合物吸收、分布、排泄相关指标 Table 1 Compound absorption , distribution , and excretion related indicators

化合物	血脑屏障	人体小肠吸收	Caco-2细胞通 P-糖蛋白底物 肾有机阴离子转 生物的 运性 运体抑制剂	条解度 亚细胞定位
雷公藤甲素	+	+	+ + -	线粒体
雷公藤氯内酯醇	+	+	- +	线粒体
雷公藤红素	+	+	+ +	线粒体
去甲泽拉木醛	+	+	-	线粒体
雷公藤春碱	+	+	+	线粒体
雷公藤新碱	+	+	<u>///</u> +	线粒体

表2 定量预测指标 Table 2 Quantitative predictor

化合物	水溶性	Caco-2 通透性/cm·s <sup>-1</sup>	大鼠急性毒性/mol·kg-l	鱼毒性/mg·L-l	四膜虫毒性 /μg·L <sup>-1</sup>
雷公藤甲素	-4.515 4	1.388 9	2.355 3	0.286 9	0.945 8
雷公藤氯内酯醇	-4.462 8	0.893 9	2.333 3	0.492 2	0.863 1
雷公藤红素	-3.8627	1.173 7	1.826 2	0.611 7	0.939 3
去甲泽拉木醛	-4.329 8	0.759 0	2.492 1	0.054 5	1.405 9
雷公藤春碱	-3.4364	0.600 1	3.034 3	0.990 1	0.757 5
雷公藤新碱	-3.6099	0.886 3	3.085 4	0.633 1	0.842 0

#### 2.1.2 化合物体内代谢相关指标

预测化合物是否为 CYP450 的底物及抑制剂,本研究中的化合物均为 CYP3A4 酶的底物,除去甲泽拉木醛为 CYP1A2 的抑制剂外,其余化合物均不是其余亚型的 CYP 酶的底物或抑制剂,CYP 酶的总抑制率均处于较低水平,见表 3。

# 表3化合物代谢相关指标

化合物	CYP2A9 物	底CYP2D6 物	底CYP3A4 物	底CYP1A2 制剂	抑CYP2C9 制剂	抑CYP2D6 制剂	抑CYP2C19 制剂	抑CYP3A4 制剂	抑CYP 综合抑制 剂
雷公藤甲素	=	=	+	=	=	_	_	_	低
雷公藤氯内酯醇	_	_	+	_	_	_	_	_	低
雷公藤红素	_	_	+	_	_	_	_	_	低
去甲泽拉木醛	_	_	+	+	_	_	_	_	低
雷公藤春碱	_	_	+	_	_	_	_	_	低
雷公藤新碱	_	_	+	_	_	_	_	_	低

#### 2.1.3 化合物毒性相关指标

雷公藤主要化学成分对 human ether-a-go-go-related gene inhibition (HERG) 相关基因的抑制性均较 弱,无 Ames mutagenicity (AME 致畸性), 大部分具有较高的鱼毒性、四膜虫毒性、蜂毒性, 生物碱 类成分具有较低的蜂毒性。值得注意的是,6种成分都不是致癌物,但是根据 median toxic dose (TD50) 值评定的致癌性警戒中, 雷公藤氯内酯处于危险等级, 具体指标见表 4。在定量预测中, 生物 碱的大鼠急性毒性相对较大,具体指标见表 2。

表4化合物毒性相关指标 Table 4 Compound toxicity related indicators

化合物	HERG 相关基因抑制性	AME 致畸性 致癌性	致癌性警戒	鱼毒性	四膜虫毒性	蜂毒性	急性口服毒 性
雷公藤甲素	弱		无需	高	高	高	
雷公藤氯内酯醇	弱	- ( -	危险	高	高	高	
雷公藤红素	弱	-\ \	无需	高	高	高	
去甲泽拉木醛	弱	/	无需	高	高	高	
雷公藤春碱	弱	// <del>/</del>	无需	高	高	低	
雷公藤新碱	弱	/ -	无需	高	高	低	

## 2.2 化合物潜在靶点预测

经 TCMSP, SWISS, STICH 数据库预测、去重后共得到靶点 65 个, 具体见表 5。


#### 表5 雷公藤主要化学成分潜在靶点

Table 5 Potential chemical constituents of Tripterygium wilfordii

基因	蛋白
NR3C1	glucocorticoid receptor
VEGFA	vascular endothelial growth factor A
CCND1	G <sub>1</sub> /S-specific cyclin-D1
BCL2	apoptosis regulator Bcl-2
BCL2L1 BAX	Bcl-2-like protein 1 apoptosis regulator BAX
FLT1	vascular endothelial growth factor receptor 1
KDR	vascular endothelial growth factor receptor 2
MMP9	matrix metalloproteinase-9
JUN	transcription factor AP-1
PTGS2	prostaglandin G/H synthase 2
BIRC5	baculoviral IAP repeat-containing protein 5
BIRC2	baculoviral IAP repeat-containing protein 2
CFLAR	CASP8 and FADD-like apoptosis regulator
AKR1B1	aldose reductase
CDC37	Hsp90 co-chaperone Cdc37
MMP2	72 kDa type IV collagenase
TIMP1	metalloproteinase inhibitor 1
TIMP2	metalloproteinase inhibitor 2
MMP1	interstitial collagenase
MYC	Myc proto-oncogene protein
FN1	fibronectin
COL7A1	collagen alpha-1(VII) chain
TGFB1	transforming growth factor beta-1
COL4A4	collagen alpha-4(IV) chain
TLR9	Toll-like receptor 9
AKR1B10	Aldo-keto reductase family 1 member B10
AKR1B15 PTPN6	Aldo-keto reductase family 1 member B15 tyrosine-protein phosphatase non-receptor type 6
PTPN11	tyrosine-protein phosphatase non-receptor type of
HSF1	heat shock factor protein 1
SENP1	sentrin-specific protease 1
TNFRSF10	Atumor necrosis factor receptor superfamily member 10A
TNFRSF10 MAPK8	
TNFRSF10 MAPK8 TNF	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor
	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor
TNFRSF10 MAPK8 TNF HSP90AA1	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha
TNFRSF10 MAPK8 TNF HSP90AA1 IL6	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS COKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mcl-
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mcl-interleukin-2
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TF53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CD86	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD80
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CD86 CXCR4	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CD86 CXCR4 BIRC3	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CD86 CXCR4 BIRC3 CD274	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets-interleukin-8 induced myeloid leukemia cell differentiation protein Mcl-interleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3 programmed cell death 1 ligand 1
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CD86 CXCR4 BIRC3 CD274 IL23A	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mcl-interleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3 programmed cell death 1 ligand 1 interleukin-23 subunit alpha
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CCN86 CXCR4 BIRC3 CD274 IL23A CCR7	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/betrinterleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3 programmed cell death 1 ligand 1 interleukin-23 subunit alpha C-C chemokine receptor type 7
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CCN86 CXCR4 BIRC3 CD274 IL23A CCR7 CD1A	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3 programmed cell death 1 ligand 1 interleukin-23 subunit alpha C-C chemokine receptor type 7 T-cell surface glycoprotein CD1a
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CD86 CXCR4 BIRC3 CD274 IL23A CCR7 CD1A CD40	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD80 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3 programmed cell death 1 ligand 1 interleukin-23 subunit alpha C-C chemokine receptor type 7 T-cell surface glycoprotein CD1a tumor necrosis factor receptor superfamily member 5
TNFRSF10 MAPK8 TNF HSP90AA1 IL6 HMOX1 RELA STAT3 FOS CDKN1A PLAU TNF CASP3 TP53 STAT1 CXCL8 MCL1 IL2 IFNG IL4 PTGS1 CD80 CCN86 CXCR4 BIRC3 CD274 IL23A CCR7 CD1A	Atumor necrosis factor receptor superfamily member 10A mitogen-activated protein kinase 8 tumor necrosis factor heat shock protein HSP 90-alpha interleukin-6 heme oxygenase 1 transcription factor p65 signal transducer and activator of transcription 3 proto-oncogene c-Fos cyclin-dependent kinase inhibitor 1 urokinase-type plasminogen activator tumor necrosis factor caspase-3 cellular tumor antigen p53 signal transducer and activator of transcription 1-alpha/bets interleukin-8 induced myeloid leukemia cell differentiation protein Mclinterleukin-2 interferon gamma interleukin-4 prostaglandin G/H synthase 1 T-lymphocyte activation antigen CD86 C-X-C chemokine receptor type 4 baculoviral IAP repeat-containing protein 3 programmed cell death 1 ligand 1 interleukin-23 subunit alpha C-C chemokine receptor type 7 T-cell surface glycoprotein CD1a

#### 2.3 潜在靶点富集分析

为阐明雷公藤中主要成分的作用机制,对所预测的 65 个靶点输入 DAVID 数据库进行通路富集分析 共得到 82 条通路,根据 P 进行筛选,P < 0.001 的通路共 50 条,涉及癌症信号通路(pathways in cancer)、乙肝(hepatitis B)、类风湿性关节炎(rheumatoid arthritis)、美洲锥虫病[chagas disease (American trypanosomiasis)]、Toll 样受体信号通路(Toll-like receptor signaling pathway)、细胞凋亡(apoptosis)、结肠癌(colorectal cancer)、NF-кB 信号通路(NF-kappa B signaling pathway)等,见表 5 。根据靶标命中数量进行排序,对排名前 20 的通路导入 Omicshare 平台进行可视化处理,见图 1 。



纵轴为通路名称,横轴为 Rich Factor 值,值越大,表明通路富集程度越高;点的大小表示富集到的靶点数量;点的颜色由红色到绿色 表明 P 由小到大。

图 1 雷公藤主要成分富集通路气泡图(前 20) Fig.1 The main component of *Tripterygium wilfordii* enrichment pathway bubble map (top 20)

#### 2.4 靶点-通路(T-P)网络构建及拓扑分析

根据筛选所得到的 50 条通路,以及其相关靶点导入 Cytoscape 3.3.0 进行靶点-通路 (T-P) 网络的构建。共得到节点 104 个,边 539 条,见图 2,具体信息见表 6。对网络进行拓扑参数分析,其中,度中心性是度量节点局部中心性的重要参数,是指节点的直接邻节点数目,认为一个节点的直接相连的节

点数目越多,影响力就越大,用该参数衡量节点重要性简单直观<sup>[16]</sup>。RELA,TNF,IL6,JUN,MAPK8 等靶点在网络具有较高的度中心性,说明这些靶点在雷公藤发挥药效或产生毒性的过程中具有重要作用,见表 7。




图 2 雷公藤主要成分"靶点-通路"网络 Fig2 The main component of *Tripterygium wilfordii* "target-pathway" network

表6富集分析中通路信息(前10) Table 6 Pathway information in enrichment analysis (top 10)

Table 6 Pathway information in enrichment analysis (top 10)

通路	靶标命中数量	P
hsa05200:pathways in cancer	29	1.71×10 <sup>-19</sup>
hsa05161:hepatitis B	19	1.25×10 <sup>-16</sup>
hsa05323:rheumatoid arthritis	18	3.61×10 <sup>-9</sup>
hsa05142:chagas disease (American rypanosomiasis)	16	$1.08 \times 10^{-10}$
hsa04620:Toll-like receptor signaling pathway	14	1.55×10 <sup>-9</sup>
hsa04210:apoptosis	14	2.96×10 <sup>-9</sup>
hsa05210:colorectal cancer	14	6.98×10 <sup>-8</sup>
hsa05205:proteoglycans in cancer	14	2.45×10 <sup>-7</sup>
hsa05321:inflammatory bowel disease (IBD)	13	$8.84 \times 10^{-12}$
hsa04064:NF-kappa B signaling pathway	13	6.69×10 <sup>-11</sup>

表7靶点-通路(T-P)网络中靶点信息(前10)

Table 7 Target Information in target-path (T-P) networks (Top 10)

靶点	degree
RELA	36
TNF	30
IL6	26
JUN	23
MAPK8	23
TP53	21
IFGN	21
TGFB1	20
CXCL8	19
CASP3	18

## 3 讨论

### 3.1 雷公藤药效作用机制分析

#### 3.1.1 雷公藤用于免疫性疾病的治疗

雷公藤在临床应用上多用于治疗免疫性疾病,具有显著的抗炎镇痛、调节免疫的作用,对类风湿性关节炎疗(RA)效显著<sup>[17]</sup>。NF-κB 信号通路(NF-kappa B signaling pathway)、TNF-α 信号通路(TNF signaling pathway)、Toll 样受体信号通路(Toll-like receptor signaling pathway)、Jak-STAT 信号通路(Jak-STAT signaling pathway)等同样与免疫性疾病有关<sup>[18]</sup>。

炎症通路 NF-κB 信号通路(NF-kappa B signaling pathway)、TNF- $\alpha$  信号通路(TNF signaling pathway)在 RA 的治疗中发挥重要作用。IL-1 和 TNF- $\alpha$  在 RA 发病中的作用主要表现在对免疫和炎症细胞的局部作用,促进滑膜纤维母细胞和软骨细胞产生前列腺素和胶原酶,导致关节软骨和骨质破坏。TNF- $\alpha$  通过介导破骨细胞的异常激活或蛋白水解酶的产生在骨破坏中发挥作用[19]。谈发明等[20]发现,雷公藤氯内酯醇能降低佐剂性关节炎大鼠的 IL-1 $\beta$  和 TNF- $\alpha$ 水平。雷公藤甲素能抑制人支气管上皮细胞生成 TNF- $\alpha$ 、白介素-1 $\beta$ 、白介素-6 和白介素-8(IL-1 $\beta$ ,IL-6,IL-8)等,也可通过减弱 Toll 样受体信号来抑制促炎反应,减轻炎症的发生[21]。有报道称,早期炎性关节炎患者滑膜组织局部 NF-κB1 呈现高表达,在关节破坏中发挥重要作用[22]。雷公藤甲素可降低胶原诱导的关节炎(CIA)模型大鼠的滑膜细胞NF-κB 的表达,降低炎症因子表达,促进抑炎因子的表达对 RA 起到治疗作用[23]。

Toll 样受体(Toll-likerecep-tors,TLRs)TLRs 是一类重要的模式识别受体,在相关的免疫调节细胞及免疫效应细胞表面或胞内广泛存在。TLRs 可介导炎症因子、趋化因子的产生也可以诱导巨噬细胞等免疫细胞的功能发生改变。Ni 等<sup>[24]</sup>研究发现雷公藤红素可以通过抑制 Toll 样受体 4(Toll-like receptor 4, TLR-4)调整 NF-κB 因子的活性从而抑制 LPS 诱导血管生成。张敏等<sup>[25]</sup>对雷公藤多苷治疗变应性鼻炎的机制进行研究,发现雷公藤多苷可通过影响 TLR-NF-κB 信号转导通路,降低 TLR4 及 NF-κB 的表达发挥免疫调节作用。

JAK/STAT 信号通路是多种细胞因子和生长因子在细胞内传递信号的共同途径,Zhang 等<sup>[26]</sup>发现雷公藤氯内酯醇能下调 ERK1/2-NF-κB 信号通路和 JAK/STAT 信号通路,从而治疗自身免疫性脑脊髓膜炎。雷公藤红素也能调节促炎细胞因子、氨基末端激酶(JNK)、血红素氧化酶-1(HO-1)、诱导型一氧化氮合酶(iNOS)、血管内皮生长因子(VEGF)的表达,在炎症和自身免疫疾病方面起到治疗作用<sup>[27]</sup>。

#### 3.1.2 雷公藤的抗癌作用

富集通路结果显示,雷公藤主要成分可作用于结肠癌(colorectal cancer)、膀胱癌(bladder cancer)、小细胞肺癌(small cell lung cancer)等癌症通路以及癌症中蛋白多糖的调控(proteoglycans in cancer)及转录调控通路(transcriptional misregulation in cancer)等,癌症信号通路(pathways in cancer)根据命中靶标数量以及P排序中均处于首位,说明雷公藤具有潜在的抗癌作用。在靶点-通路网络中,RELA,JUN,MAPK8,TP53,CXCL8 等与癌症相关的蛋白也具有较高的度中心性,在网络中发挥重要作用。雷公藤的抗肿瘤作用与 DNA,RNA 及蛋白质的合成有关,并抑制磷酸果糖激酶,抑制

肝糖原合成,同时调节抗体的免疫功能。大量实验研究表明,雷公藤可通过抑制肿瘤细胞生长、阻滞细胞周期和诱导凋亡,调控 MAPK 信号通路、P53 蛋白表达等途径抑制多种恶性肿瘤的侵袭和转移作用,如鼻咽癌、食管癌、胃癌、肝癌、乳腺癌以及胰腺癌等<sup>[2,28]</sup>。多种癌细胞表达细胞表面存在 CXC 趋化因子受体 4(CXCR4)。基质细胞衍生因子-1(SDF-1)与 CXCR4 结合后将癌细胞送往特定器官或组织(如肺、肝、淋巴结)。研究表明,雷公藤甲素作用于结肠癌细胞后,能抑制 CXCR4 表达,进而抑制癌细胞的侵袭和转移,同时抑制凝血酶、TNF 和 TGF-β 受体的表达<sup>[29]</sup>。XIE 等<sup>[30]</sup>发现雷公藤甲素可能作用于JNK 和 ERK 信号通路来抑制人肺癌耐药细胞的增殖进而发挥抗癌作用,且其抑制作用呈剂量依赖性。

#### 3.2 雷公藤毒性作用机制

现代研究表明,雷公藤的主要化学成分既是有效成分也是毒性成分。雷公藤毒不良反应强且高发, 并涉及多器官系统,包括胃肠道毒性、生殖系统毒性、血液和造血系统毒性、肝毒性、肾脏毒性、心血 管毒性等[31-32]。研究表明,二萜类成分、生物碱类成分、三萜类成分的毒性依次减弱。其中,二萜类 成分对心、肝、胃肠道及骨髓有明显毒副作用;生物碱类物质损伤肝、破坏红细胞、引起进行性贫 血[1]。ADMET 结果显示,对于 CYP 的抑制率较低,说明在进入体内后会保持较高的血药浓度。同时, 各化合物都可以作为CYP3A4酶的底物与其结合,且各个化合物存在的细胞器均为线粒体,这可能与雷 公藤对肝线粒体具有损伤作用进而导致肝毒性有关[33]。但也有学者发现,雷公藤甲素对 CYP3A 呈时间 和剂量依赖性抑制,进而造成雷公藤在肝脏蓄积,增加肝毒性[34]。基因富集的结果显示,雷公藤可作 用于细胞凋亡途径(apoptosis),调控 Bax, Bcl-2 等细胞的表达。雷公藤主要成分对多种细胞存在凋 亡作用,这是其发挥药效的机制之一,同时也是产生毒性的机制。YAO 等[35]发现,雷公藤甲素可下调 抗细胞凋亡 Bc1-2 蛋白水平, 上调促细胞凋亡 Bax 蛋白水平, 通过线粒体途径诱导细胞凋亡从而产生细 胞毒性。冯雪等<sup>[36]</sup>对雷公藤制剂的肾毒性进行循证评价,其导致肾毒性的发生率为 5.81%, 主要表现为 尿素氮、肌酐升高,肾功能异常,肾功能损害,肾功能不全,血尿,急性肾功能衰竭。任强等[37]观察 雷公藤多苷对大鼠的肾损伤情况,结果表明,雷公藤多苷通过 NF-κB 这条信号转导通路诱导肾细胞凋 亡是其毒性作用的可能机制之一。有报道称,雷公藤具有生殖毒性,吴建元等[<sup>38</sup>]在雷公藤片对小鼠睾 丸组织毒性作用的研究中发现,睾丸组织凋亡可能与 NF-xB 表达的过度抑制进而导致 eNOS 显下调、 Fas-L 和 Bax 的表达上调有关。

#### 4 结论

本研究通过网络药理学的方法,对雷公藤主要成分雷公藤甲素、雷公藤氯内酯醇、雷公藤红素、去甲泽拉木醛、雷公藤春碱、雷公藤新碱的效毒作用机制进行预测研究。雷公藤可以通过调控炎症信号通路、Toll 样受体信号通路等,对免疫性疾病如类风湿性关节炎起到良好的治疗作用。雷公藤也可以作用于癌症信号通路,调控 DNA,RNA 的转录及蛋白质合成,在抗肿瘤作用上也发挥着重要作用。雷公藤的不良反应累及多器官系统,其主要成分可诱导细胞凋亡,这是导致雷公藤具有毒性的重要作用机制之一,同时,雷公藤可作用于肝脏代谢酶系统,导致雷公藤在体内蓄积进而产生毒性。

#### [参考文献]

- [1] 薛璟, 贾晓斌, 谭晓斌, 等. 雷公藤化学成分及其毒性研究进展[J]. 中华中医药杂志, 2010, 25 (5): 726.
- [2] 刘玉凤,潘丽,南丽红,等. 雷公藤药理作用研究进展[J]. 亚太传统医药, 2014, 10 (9): 37.
- [3] 蒋且英,罗素花,杨瑞昆,等. 炮制对雷公藤毒效及其化学成分影响的研究进展[J]. 中国实验方剂学杂志, 2018, 24(4): 216.
- [4] 朱冬宁,陈驰,王淑美,等. 网络药理学在中医药研究领域的应用进展[J]. 广东化工, 2018, 45 (7): 157.
- [5] 张彦琼, 李梢. 网络药理学与中医药现代研究的若干进展[J]. 中国药理学与毒理学杂志, 2015, 29(6): 883.
- [6] Kim S, Thiessen P A, Bolton E E, et al. PubChem substance and compound databases[J]. Nucleic Acids Res, 2016, 44:D1202.
- [7] Cheng Feixiong, Li Weihua, Zhou Yadi, et al. admetSAR: a comprehensive source and free tool for evaluating chemical ADMET properties[J]. J Chem Inf Model, 2012, 52(11): 3099.
- [8] Davis A M, Riley R J. Predictive ADMET studies, the challenges and the opportunities[J]. Curr Opin Chem Biol, 2004, 8(4):378.
- [9] Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014, 6(1):13.
- [10] Gfeller D, Grosdidier A, Wirth M, et al. SwissTargetPrediction: a web server for target prediction of bioactive small molecules[J]. Nucleic Acids Res, 2014, 42:32.
- [11] 孙雨辉, 陆景坤, 王健, 等. 基于网络药理学的三味檀香散治疗冠心病的机制初探[J]. 中国新药与临床杂, 2018, 37 (5): 272.

[12] Damian S, Alberto S, Christian V M, et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data[J]. Nucleic Acids Res, 2016, 44:D380.

- [13] Consortium U P. UniProt: a hub for protein information[J]. Nucleic Acids Res, 2015, 43:204.
- [14] Jiao X, Sherman B T, Huang W D, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis[J]. Bioinformatics, 2012, 28(13):1805.
- [15] 章亮,陈泽慧,陈韩英,等.基于网络药理学的白屈菜抗肿瘤分子机制研究[J].中草药,2018,49(3):646.
- [16]周文霞,王同兴,程肖蕊,等. 网络药理学研究中的网络分析技术[J]. 国际药学研究杂志,2016,43(3):399.
- [17] 郭梦如,何东仪.雷公藤治疗类风湿关节炎的研究进展[J].风湿病与关节炎,2013,2(2):58.
- [18] 吕邵娃,王秋实,赵爽,等.中药调控类风湿性关节炎核因子 κB 信号通路的研究进展[J].细胞与分子免疫学杂志,2015,31(11): 1580.
- [19] 曾小威,李世刚. 类风湿性关节炎治疗及免疫分子机制研究进展[J]. 中华实用诊断与治疗杂志,2015,29(11):1044.
- [20] 谈发明, 刘颜, 陈茂华, 等. 雷公藤内酯醇对佐剂性关节炎大鼠抗炎作用的实验研究[J]. 中药新药与临床药理, 2014, 25(2): 176.
- [21]刘文成,谭布珍,方玉婷,等. 植物雷公藤主要抗癌抗炎活性成分研究进展[J]. 中国临床药理学与治疗学,2017,22(3):355.
- [22] 郭江燕, 高梓珊, 姜姝姝, 等. IL-17和 NF-кB 通路与类风湿性关节炎的相关性研究[J]. 长春中医药大学学报, 2015, 31(1): 192.
- [23] 胡永红,曾克勤,张明敏,等.雷公藤甲素对胶原诱导的关节炎大鼠滑膜细胞核转录因子 κB 表达与活性的影响[J].中华风湿病学杂志,2004(9):515.
- [24] Ni H,Zhao W,Kong X,et al.Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclearfactor-kappa B activation[J].Acta Haematol,2014,131 (2):102.
- [25] 张敏, 王守安, 刘黎星. 雷公藤多苷干预 TLR-NF-κB 通路发挥免疫抑制作用[J]. 中草药, 2014, 45 (9): 1288.
- [26] Zhang J, Zeng Y Q, Zhang J, et al. Tripchlorolide ameliorates experimental autoimmune encephalomyelitis by down □regulating ERK1/2 □ NF □ κB and JAK/STAT signaling pathways [J]. J Neurochem, 2015, 133(1):104.
- [27] Kannaiyan R, Shanmugam M K, Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer[J]. Cancer Lett, 2011, 303(1):9.
- [28] 徐烨, 郁峰, 崔焌辉, 等. 雷公藤红素促进 RIP1 蛋白的去泛素化增强 TNF-α 对结肠癌细胞的凋亡诱导活性的研究[J]. 中国现代应用药 学, 2017, 34 (1): 43.
- [29] 刘文成, 谭布珍, 方玉婷, 等. 植物雷公藤主要抗癌抗炎活性成分研究进展[J]. 中国临床药理学与治疗学, 2017, 22 (3): 355.
- [30] Xie C Q, Zhou P, Zuo J, et al. Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Aktsignaling pathways[J]. Oncol Lett, 2016, 12(5):3586.
- [31] 陶玲, 肖芳, 朱卫丰, 等. 雷公藤减毒研究进展[J]. 中国实验方剂学杂志, 2017, 23 (5): 229.
- [32] 昊霞, 王忠震, 林兵, 等. 雷公藤毒性作用机制研究进展[J], 中国医院药学杂志, 2015, 35 (16): 1519.
- [33] Shen G, Zhuang X, Xiao W, et al. Role of CYP3A in regulating hepatic clearance and hepatotoxicity of triptolide in rat liver microsomes and sandwich-cultured hepatocytes[J]. Food Chem Toxicol, 2014, 71(8):90.
- [34] Shen G, Zhuang X, Xiao W, et al. Role of CYP3A in regulating hepatic clearance and hepatotoxicity of triptolide in rat liver microsomes and sandwich-cultured hepatocytes[J]. Food Chem Toxicol, 2014, 71(8):90.
- [35] Yao J, Jiang Z, Duan W, et al. Involvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cells[J]. Biol Pharm Bull, 2008, 31(4):592.
- [36] 冯雪, 方赛男, 高雨鑫, 等. 雷公藤制剂安全性的循证评价研究[J]. 中国中药杂志, 2018, 43 (3): 425.
- [37]任强, 岑国栋, 高永翔. 雷公藤多苷诱导大鼠肾细胞凋亡的 NF-κB 信号转导通路机制研究[J]. 成都中医药大学学报, 2011, 34 (2): 39.
- [38] 吴建元, 肖玉玲, 丁虹, 等、雷公藤片对小鼠睾丸组织的毒性作用及其分子机制研究[J]. 中药材, 2005, 28 (3): 207.